UC Davis Health Clinical Studies

Active surveillance, chemotherapy in treating pediatric and adult patients with germ cell tumors

How well does chemotherapy, (bleomycin, carboplatin, etoposide, or cisplatin), active surveillance work in patients with germ cell tumors?

This study looks at how well active surveillance, bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Other study, Phase 3
Any, age 1 to 49 years old

Two different types of radiotherapy, and hormone therapy for treatment of prostate cancer

SBRT boost (high doses of radiation to tumor ), IMRT (low radiation to normal tissues, optimal radiation to cancer cells), hormone therapy

The purpose of this study is to find out the side effects and effectiveness of stereotactic body radiotherapy (SBRT) boost in patients with intermediate and high risk prostate cancer when used with intensity modulated radiotherapy (IMRT) and hormone therapy. SBRT boost is a treatment method used to deliver high doses of radiation to the tumor in your prostate. This will require placement of transponders called permanent Beacon transponders®. Beacon transponders®, used with the Calypso® 4D Localization System™, have been approved by the U.S. Food and Drug Administration for use in the prostate. The transponders work with the Calypso® system to track the exact location of your prostate tumor. Standard radiation techniques cannot avoid delivering radiation to normal tissues that do not need to get radiation. IMRT tries to lower the amount of radiation that normal tissues receive, while still delivering the desired amount of radiation to your cancer and to areas that the study doctor thinks may have cancer cells, such as lymph nodes in the pelvis. IMRT does this by using multiple, computer-controlled radiation beams aimed at your cancer from different directions. Hormone therapy is standard of care for your cancer and works by lowering the levels of testosterone in the body, which are naturally occurring male hormones. Testosterone is involved in the growth of cancer cells in the prostate. Drugs that reduce or block testosterone (hormone therapy) can cause some prostate cancer cells to die and others to become sick so that they don’t grow. Some patients treated with a combination of these drugs and radiation therapy have a greater chance of not having the cancer return when compared to men treated with radiation alone. You will take injections of a luteinizing hormone releasing hormone (LHRH) agonist, either under the skin or in the muscle , and you will take a pill, bicalutamide once per day. The injected LHRH agonists (otherwise known as Lupron® and Zoladex® - your radiation oncologist will decide which one of these you will receive) is a drug which reduces the amount of testosterone in the body. Prostate cancer cells are hormone dependent. This means they need hormones (testosterone) to grow. By blocking the formation of testosterone, LHRH agonists block the formation of more cancer cells. The pill, Casodex®, will interfere with the action of any remaining testosterone. Casodex® will do this by binding to the prostate instead of testosterone and therefore blocking the growth of more cancer cells.

Radiation study
Male, age 18 to 100 years old

Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Study medicine, PDMX1001/Niclosamide combined with approved prostate cancer drugs, abiraterone and prednisone to treat prostate cancer

This study looks at the side effects and how well abiraterone acetate, niclosamide, and prednisone work in treating patients with hormone-resistant prostate cancer. Androgens can cause the growth of prostate cells. Hormone therapy using abiraterone acetate may fight prostate cancer by lowering the amount of androgen the body makes. Niclosamide is a drug that may block another signal that can cause prostate cancer cell growth. Prednisone is a drug that can help lessen inflammation. Giving abiraterone acetate, niclosamide, and prednisone may be a better treatment for patients with hormone-resistant prostate cancer.

Drug study, Phase 2
Male, age 19 to 100 years old